

EXPRESS MAIL NO: EU169119435US
Date of Deposit: January 7, 2004

Attorney Docket No: CST-209
PAIR Customer No.: 31012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Polakiewicz, *et al*
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.
SERIAL NUMBER: 10/694,874 EXAMINER: Not yet assigned
FILING DATE: October 28, 2003 ART UNIT: Not yet assigned
FOR: ANTIBODIES SPECIFIC FOR PHOSPHORYLATED INSULIN RECEPTOR
SUBSTRATE-1/2 (SER1101/SER1149) AND USES THEREOF

January 7, 2004
Beverly, Massachusetts

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent or Application Documents:

5,621,075	5/15/1997	Kahn, et al

Foreign Patent Documents:

Other Prior Art – Non Patent Literature Documents:

Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
--

APPLICANTS: Polakiewicz, *et al*
U.S.S.N.: 10/694,874

Attorney Docket No: CST-209
PAIR No.: 31012

White, M.F., <i>Mol. Cell. Biochem.</i> 182: 3-11 (1998)
Holgado-Madruga, <i>et al.</i> , <i>Nature</i> 379: 560-564 (1996)
Moodie <i>et al.</i> , <i>J. Biol. Chem.</i> 274: 11186-11193 (1999)
Saltiel <i>et al.</i> , <i>Trends Cell. Bio.</i> 12: 65-71 (2002)
Zick Y., <i>Trends Cell Bio.</i> 11: 437-441 (2001)
Jiang <i>et al.</i> , <i>Diabetes</i> 48: 1120-1130 (1999)
Mothe <i>et al.</i> , <i>J. Bio. Chem.</i> 271: 11222-1127 (1996)
Li J., <i>J. Bio. Chem.</i> 274: 9351-9356 (1999)
Upstate Biotechnology, Inc., Cat. No. 07-247 (Ser307)
Cell Signaling Technology, Inc., Cat. No. 2388, 2386 (Ser 636/639 and 612)
Biosource, Inc., Cat. No. 44-550 (Ser616)
Aguirre <i>et al.</i> , <i>J. Biol. Chem.</i> 275: 9047-9054 (2000)
Rui <i>et al.</i> , <i>J. Clin. Invest.</i> 107: 181-189 (2001)
Aguirre <i>et al.</i> , <i>J. Biol. Chem.</i> 277: 1531-1537 (2002)
Griffin <i>et al.</i> , <i>Diabetes</i> 48: 1270-1274 (1999)
Itani <i>et al.</i> , <i>Metabolism</i> 50: 553-557
Qu <i>et al.</i> , <i>J. Endocrinology.</i> 162: 207-214 (1999)
Chalfant <i>et al.</i> , <i>Endocrinology</i> 141: 2773-2778 (2000)

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.


Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Reference No. CST-209.

Respectfully submitted,



James Gregory Cullem, Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
166B Cummings Center
Beverly, MA 01915
(978) 867-2311

Dated: 1/7/04



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/694,874
	Filing Date	October 28, 2003
	First Named Inventor	Polakiewicz, <i>et al</i>
	Group Art Unit	Not Yet Known
	Examiner Name	Not Yet Known
	Attorney Docket Number	CST- 209

U.S. PATENT OR APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Publication Date	Name of Patentee(s) or Applicant(s)	Co-Pending?	Filing Date If Appropriate
	AA	5,621,075	05/15/97		Kahn, <i>et al</i>	No	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CA	Saltiel <i>et al.</i> , <i>Nature</i> 414: 799-806 (2001)
	CB	White, M.F., <i>Mol. Cell. Biochem.</i> 182: 3-11 (1998)
	CC	Holgado-Madruga <i>et al.</i> , <i>Nature</i> 379: 560-564 (1996)
	CD	Moodie <i>et al.</i> , <i>J. Biol. Chem.</i> 274: 11186-11193 (1999)
	CE	Saltiel <i>et al.</i> , <i>Trends Cell Bio.</i> 12: 65-71 (2002)
	CF	Zick Y., <i>Trends Cell bio.</i> 11: 437-441 (2001)
	CG	Jiang <i>et al.</i> , <i>Diabetes</i> 48: 1120-1130 (1999)
	CH	Mothe <i>et al.</i> , <i>J. Biol. Chem.</i> 271: 9351-9356 (1996)
	CI	Li J., <i>J. Biol. Chem.</i> 274: 9351-9356 (1999)
	CJ	Upstate Biotechnology, Inc., Cat. No. 07-247 (Ser307)
	CK	Cell Signaling Technology, Inc., Cat. No. 2388, 2386 (Ser 636/639 and 612)
	CL	Biosource, Inc., Cat. No. 44-550 (Ser616)
	CM	Aguirre <i>et al.</i> , <i>J. Biol. Chem.</i> 275: 9047-9054 (2000)
	CN	Rui <i>et al.</i> , <i>J. Clin. Invest.</i> 107: 181-189 (2001)
	CO	Aguirre <i>et al.</i> , <i>J. Biol. Chem.</i> 277: 1531-1537 (2002)
	CP	Griffin <i>et al.</i> , <i>Diabetes</i> 48: 1270-1274 (1999)
	CQ	Itani <i>et al.</i> , <i>Metabolism</i> 50: 553-557 (2001)
	CR	Qu <i>et al.</i> , <i>J. Endocrinol.</i> 162: 207-214 (1999)
	CS	Chalfant <i>et al.</i> , <i>Endocrinology</i> 141: 2773-2778 (2000)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120; 37 C.F.R. §1.98(d) (continuation, continuation-in-part, and divisional applications).

^ a copy of this reference (AI) is not presently provided as it is not yet available to Applicants; a copy will be forwarded in a Supplemental IDS upon Applicants' receipt of the reference.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.